

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON'S DISEASE

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that ALMB-0166 developed by the Group has obtained approval from the National Medical Products Administration of the People's Republic of China to conduct a Phase II clinical trial in China to evaluate its efficacy in patients with Parkinson's disease.

ALMB-0166, a first-in-class humanized monoclonal antibody inhibitor targeting a novel hemichannel membrane protein, Connexin 43 (Cx43), was independently developed by the Company's subsidiary, AlaMab Therapeutics Inc., for the treatment of Parkinson's disease, acute ischemic stroke, acute spinal cord injury, and other neurological disorders.

Parkinson's disease is the world's second most common neurodegenerative disorder, characterized pathologically by the progressive degeneration of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies. The etiology of Parkinson's disease remains incompletely understood. Its clinical manifestations are notable for motor symptoms such as resting tremors, muscular rigidity, bradykinesia, and postural instability, as well as non-motor symptoms including sleep disorders, cognitive impairment, and psychiatric disturbances. Both motor and non-motor symptoms worsen as the disease progresses, severely affecting patients' quality of life and imposing heavy economic and caregiving burdens on families and society. Currently, therapeutic drugs and approaches for Parkinson's disease, including levodopa-based therapies, only provide symptomatic relief without reversing disease progression or achieving a cure. Therefore, given the limitations of current therapeutic approaches, there is an urgent need in the field of Parkinson's disease for the development of novel therapeutic drugs and approaches to effectively delay disease progression and improve patients' quality of life.

ALMB-0166 exerts its effect by targeting Cx43 hemichannels, inhibiting the release and spread of neuroinflammatory mediators, and thereby maximizing neuroprotection. Preclinical studies in subacute and chronic Parkinson's disease animal models demonstrated that ALMB-0166 significantly prevented dopamine depletion in the brain, markedly restored behavioral performance and functional capacity, and exhibited a favorable dose-response relationship.

The Group will make every effort to advance the clinical development of ALMB-0166 across multiple indications and strive to bring it to the market as early as possible.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 15 September 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.